SYDNEY, Jan. 20, 2026 /PRNewswire/ — Humanforce, a leading global provider of intelligent, AI-driven human capital management (HCM) solutions for frontline workforces, today announced the appointment of Cameron Partridge as Chief Growth Officer (CGO).

Cameron’s appointment is part of a drive to strengthen Humanforce’s senior leadership capability across Australia, the UK, and North America, following several high-level executive hires in recent months. In his role, he will lead the evolution of Humanforce’s global brand, mature its commercial operating model and accelerate expansion across key international markets.

Cameron is a globally recognised AI strategy and commercial leader with experience across private-equity-backed companies, high-growth scaleups and Fortune 50 organisations, including nearly a decade operating in the United States. Most recently, Cameron served as CMO of Invisible Technologies, one of North America’s fastest-growing AI companies, where he helped accelerate and scale commercial growth and operations, supporting enterprise customers such as DoorDash, Microsoft and AWS. He has previously held senior leadership roles at Macquarie Group, BBDO, and GE. 

Cameron said he was drawn to Humanforce by the strength of the executive team, the company’s leading position in the HR tech landscape and the strong scalability opportunity.

“Clayton and the senior leadership team are building Humanforce with an ambition and intensity that is rare in mid-market SaaS,” Cameron said. “The recent executive appointments signal a disciplined shift toward scale, accountability and global execution. It’s the kind of environment where meaningful, sustained growth can be created – not just talked about.”

Humanforce powers frontline workforces across healthcare, hospitality, childcare, retail, aged care, venues and major sporting organisations. Customers include Accor, Flight Centre, Hungry Jack’s, Vodafone, Fujitsu, Alfred Health, Hostplus — organisations operating in high-regulation, high-complexity environments where workforce management is mission-critical.

Humanforce has strengthened its leadership in frontline HCM by expanding its comprehensive, enterprise-ready platform across talent acquisition, engagement and financial wellbeing. This integrated model supports the full employee lifecycle within a single platform designed for scale, compliance and operational complexity.

“As AI reshapes knowledge and desk work, frontline labour is becoming more essential and more complex,” Cameron said. “For years, organisations had to choose between fragmented best-in-class tools or broad suites that underdelivered. Humanforce is the first platform to offer both – a full, integrated suite with genuinely best-in-class capability across compliance, scheduling, payroll and workforce intelligence. That’s a rare and strong place to be in today’s market.”

Humanforce CEO Clayton Pyne said Cameron’s appointment is a key step in strengthening the company’s position as the global leader in frontline HCM.

“Cameron has operated at the sharp edge of AI and modern commercial systems, bringing global experience and real scaling pedigree from high-growth companies,” said Clayton Pyne, Chief Executive Officer of Humanforce. “As we enter a new stage of global expansion and sharpen our focus on upmarket opportunities, his leadership will be central to how we shape our commercial engine, strengthen our market position and scale with discipline and speed.”

-ends-

About Humanforce

Humanforce provides the market leading, employee-centred, intelligent and compliant HCM suite for frontline and flexible workforces, offering highly configurable, all-in-one WFM, HR, Talent, Benefits and Payroll – without compromise. Our vision is to make work easier and life better by focusing on the employee experience (EX), and the efficiency and optimisation of businesses.

Founded in 2002, Humanforce has a 2300-strong customer base and is heading towards one million employees under management, across a wide range of industries including Aged Care, Childcare, Healthcare, Retail, Hospitality, Events & Stadia, Local Government and more. Today, we have offices across Australia, New Zealand, the United Kingdom, the Philippines, and the USA.

Customers include Accor, Flight Centre, Hungry Jack’s, Vodafone, Fujitsu, Alfred Health, Hostplus and more: https://humanforce.com

New lab advances webAI’s mission to build accessible, sovereign, and defensible intelligence for real-world deployment

AUSTIN, Texas, Jan. 20, 2026 /PRNewswire/ — webAI today announced the appointment of Dr. Paul J. Maykish as Chief Intelligence Officer and the launch of the webAI Intelligence Lab, a dedicated unit focused on building accessible, sovereign, and defensible intelligence across public sector and enterprise environments.

Dr. PJ Maykish joins webAI to lead the newly formed Intelligence Lab after serving as a Vice President for technology strategy at the Special Competitive Studies Project and Director for Technology Competition at the National Security Council. A 24-year veteran of military operations, Maykish previously directed classified research for the National Security Commission on Artificial Intelligence and commanded the U.S. Central Command’s Combined Air Operations Center, including commissioning AI programs in the ISIS war.

Under Dr. Maykish’s leadership, the Intelligence Lab will advance webAI’s long-term vision of Superintelligence built not as a single centralized model, but as a network of interoperable, domain-specific intelligence systems. These systems are designed to collaborate securely, operate locally, and compound in capability over time. All the while delivering practical, deployable improvements to webAI’s platform today.

“Our mission is simple, but non-negotiable: advance towards Artificial Superintelligence that is accessible, sovereign, and defensible,” said David Stout, founder and CEO of webAI. “We believe the future of intelligence is something you own, operate, and trust wherever it is needed. The Intelligence Lab exists to build that future.”

The webAI Intelligence Lab will focus on building systems designed for operational reliability, data sovereignty, and resilience in contested environments. Initial focus areas include:

• On-device and edge intelligence for local execution
• Architectures designed for security, integrity, and adversarial resistance
• Repeatable deployment patterns that scale across organizations and missions

“AI is rapidly becoming operational infrastructure, and the bar is rising,” said Dr. Maykish, Chief Intelligence Officer at webAI. “The Intelligence Lab will build systems that organizations can control end-to-end, from data to models to runtime, with performance and trust that hold up in the real world.”

The launch follows webAI’s recently announced funding and valuation milestone, which is accelerating hiring and investment across product, engineering, and deployment programs to meet growing demand for sovereign AI.

To learn more about webAI and the webAI Intelligence Lab, visit www.webai.com.

About webAI

webAI is the enterprise AI platform that brings AI to your data. Built for mission-critical environments, it enables organizations to build and operate private, custom models with complete data sovereignty, real-time performance, and predictable economics.

MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (NDA) for TLX591-Px (Illuccix®, Kit for the preparation of ⁶⁸Ga-PSMA-11), Telix’s lead prostate cancer imaging agent.

The NDA was submitted with Telix’s strategic partner for the Greater China region, Grand Pharmaceutical Group Limited (00512.HK, Grand Pharma). Seeking a broad label that reflects clinical utility at multiple stages of prostate cancer care, the submission includes data from the Illuccix China Pivotal Phase 3 Registration study^[1], which reported positive top-line results in December 2025^[2].

The Illuccix China study met its primary endpoint, with an overall patient-level positive predictive value (PPV) of 94.8% for the detection of tumors in patients with biochemical recurrence (BCR) of prostate cancer with TLX591-Px^[2],[3]. This confirmed that the clinical experience of TLX591-Px PSMA-PET^[4] imaging in Chinese patients is comparable to studies in non-Chinese patients. The high PPV was demonstrated even in patients with very low PSA^[5] values, and across differing metastatic locations. More than two-thirds (67.2%) of patients experienced a change in their treatment plan as a consequence of TLX591-Px PSMA-PET imaging compared with the initial plan at baseline^[3], demonstrating a major impact on clinical decision-making in Chinese patients.  

Kevin Richardson, Chief Executive Officer, Precision Medicine, Telix, commented, “Submitting this New Drug Application for TLX591-Px, the first for any of our products in China, is a major milestone for Telix and our partner Grand Pharma. Geographic expansion is core to the growth strategy for our precision medicine business, and China represents a strategically important market for Telix. We look forward to progressing regulatory approvals together with Grand Pharma and subject to NMPA approval, bringing our lead commercial imaging product to market in China to serve the needs of men living with prostate cancer.”

About Prostate Cancer in China

In China, more than 134,000 men were diagnosed with prostate cancer in 2022^[6], increasing by approximately 6% each year^[7]. In line with government policy supporting wider geographic access to nuclear medicine, the number of PET/CT cameras installed in China is expected to have surpassed 1,600 at the end of 2025^[8], compared with 133 in 2010^[9].

About Illuccix

Telix’s lead prostate imaging product, gallium-68 (⁶⁸Ga) gozetotide injection (also known as ⁶⁸Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)^[10], by the Australian Therapeutic Goods Administration (TGA)^[11], by Health Canada^[12], by the Brazilian Health Regulatory Agency (ANVISA)^[13], by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)^[14] and in 19 countries within the European Economic Area (EEA).

PSMA-PET imaging represents a significant advance in prostate cancer management, largely replacing conventional imaging methods such as bone scans and computed tomography (CT) scans as the standard of care after initial diagnosis and biochemical recurrence (BCR) in the United States. Global guidelines recognize its superior accuracy in staging primary disease and assessing BCR^[15].

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations (Global)

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)  

Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

Media Contact

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

[1] ClinicalTrials.gov ID: NCT05847348.
[2] Telix ASX disclosure 22 December 2025.
[3] Telix data on file. Illuccix China Clinical Study Report, December 2025.
[4] Imaging of prostate-specific membrane antigen with positron emission tomography.
[5] Prostate-specific antigen.
[6] Global Cancer Statistics 2022: GLOBOCAN survey. Published August 2024.
[7] Ye Dingwei et al. Lancet Oncology, 2022.
[8] Yang et al. J Nuc. Med. 2024.
[9] Goetz Partners research 2020.
[10] Telix ASX disclosure 20 December 2021.
[11] Telix ASX disclosure 2 November 2021.
[12] Telix ASX disclosure 14 October 2022.
[13] Telix ASX disclosure 18 March 2025.
[14] Telix ASX disclosure 13 February 2025.
[15] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.3.2026; EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025. ISBN 978-94-92671-29-5: https://uroweb.org/guidelines/prostate-cancer; Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2023: https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-genitourinary-cancers/clinical-practice-guidelines-prostate-cancer/eupdate-prostate-cancer-treatment-recommendations

LOS ANGELES, Jan. 20, 2026 /PRNewswire/ — GIGABYTE TECHNOLOGY Co. Ltd, a leading global manufacturer of motherboards, graphics cards, and hardware solutions, today unveiled the X870E AERO X3D WOOD at CES 2026. This new category of premium motherboards blends high-performance engineering with lifestyle-focused design.

As PCs increasingly move into open living and working spaces, X870E AERO X3D WOOD reimagines hardware as a design statement, bringing warmth and sophistication to high-end builds without compromising capability.

A New Aesthetic for a New Era of PC Design
Inspired by natural materials and modern interiors, the X870E AERO X3D WOOD reflects a shift toward design-driven hardware. The motherboard features wood-inspired accents and a premium leather pull tab, delivering a tactile and visual experience rarely seen in traditional PC components.

Designed for enthusiasts, creators, and gamers who value both form and function, X870E AERO X3D WOOD integrates naturally into lifestyle-focused PC setups, transforming hardware into a centerpiece rather than something to hide away. 

Flagship Performance Powered by AMD X3D
Beneath its refined exterior, X870E AERO X3D WOOD delivers uncompromising performance. Built on the AMD Socket AM5 platform, it supports the latest Ryzen™ 9000, 8000, and 7000 Series processors and enhances X3D performance through AI-assisted X3D Turbo Mode 2.0.

The motherboard supports DDR5 memory overclocking up to 9000MT/s and features a robust digital twin 16+2+2 phases VRM design for stable and efficient power delivery. Expansion capabilities include dual PCIe 5.0 slots for graphics cards and four M.2 slots supporting PCIe 5.0 / 4.0 x4 for ultra-fast storage.

Advanced Thermal Engineering with Elegant Integration
To maintain peak performance, X870E AERO X3D WOOD features a comprehensive thermal solution engineered for both efficiency and visual aesthetics.

Key thermal innovations include: 

• VRM Thermal Armor Advanced with high-efficiency heat pipes
• M.2 Thermal Guard L & M.2 Thermal Guard Ext.
• PCB Thermal Plate, improving thermal performance by 14% and adding structural stability. 

Next-Generation Connectivity and User-Friendly Features
Equipped with dual 5GbE LAN, Wi-Fi 7, and dual USB4 Type-C ports (DisplayPort Alt Mode/HDMI), the board includes GIGABYTE’s user-centric innovations: 

• DriverBIOS with pre-installed Wi-Fi drivers for instant network access
• M.2 EZ-Flex with a flexible patented baseplate for improved SSD cooling
• WIFI EZ-Plug for simplified antenna installation
• M.2 EZ-Latch Click & Plus for tool-free SSD installation 

For more information, please visit: 
Official Website: https://www.gigabyte.com/Motherboard/X870E-AERO-X3D-WOOD
Order Here: GIGABYTE X870E AERO X3D WOOD

AUCKLAND, New Zealand, Jan. 20, 2026 /PRNewswire/ — Jungheinrich, today, announced the Asia-Pacific launch of “AntOn by Jungheinrich“, a new value-focused material handling brand designed for businesses seeking reliable, straightforward, and cost-effective solutions for everyday operations.

AntOn by Jungheinrich delivers proven reliability, supported by German safety standards and testing expertise. Across the region, sustainability programmes and fleet modernisation initiatives are accelerating the shift toward electrified material handling equipment, reinforcing demand for lithium-ion solutions that balance performance, efficiency, and total cost of ownership.

The initial AntOn portfolio includes CBH 2.0, CBM 2.5, 3.0 and 3.5 tonne electric forklifts, delivering strong load capacities of 2,000 kg, 2,500 kg, 3,000 kg and 3,500 kg, travel speeds up to 17 km/h, and advanced lithium-ion batteries for rapid charging and extended operation, long service life, and minimal maintenance for reliable, efficient material handling in APAC markets. The portfolio is set to expand towards a full product range in the future.

The launch responds to strong growth in the Asia-Pacific’s material handling value segment, which is projected to expand at 8.1% by 2030.

In New Zealand, growth in logistics, warehousing, and infrastructure is driving demand for cost-effective, reliable material handling equipment. Rising operating costs and ESG expectations are accelerating the shift from internal combustion forklifts to electric solutions, with lithium-ion technology increasingly adopted for its lower total cost of ownership, zero maintenance, fast charging, and reliable multi-shift performance.

“The AntOn by Jungheinrich brand is a new product line combining ease of use, reliability and cost-effectiveness,” said Nadine Despineux, Member of the Board of Management, Sales at Jungheinrich. “We are specifically targeting companies that are looking for cost-effective and straightforward solutions for typical warehouse and transport requirements.”

Following a successful European debut with strong sales, AntOn by Jungheinrich is now available to customers in Asia-Pacific, supported through multi-channel sales, including e-commerce, direct sales, and selected partners and distributors.

“With more than 70 years of material handling expertise, Jungheinrich delivers end-to-end solutions supported by an established parts and service network across Asia-Pacific,” said Manojit Acharya, Vice President, Jungheinrich APAC.

For more information on the AntOn by Jungheinrich range, please visit: http://www.jungheinrich.co.nz. Interested in becoming an AntOn distributor? Please contact us directly at sales@jungheinrich.co.nz.

For media enquiries:

Jungheinrich
Daniel Lynch | daniel.lynch@jungheinrich.com.au | +61 423 922 202

Rothman & Roman (Appointed PR Agency)
Diana Estella | diana.estella@rothmanasia.com | +65 8498 9424

• Only three-in-ten (30%) CEOs confident about revenue growth in 2026 as most struggle to turn AI investment into tangible returns
• One-in-eight (12%) CEOs say AI has delivered both cost and revenue benefits, while companies that have scaled AI with strong foundations are pulling ahead
• Rising concerns about tariffs and cyber risk add to pressure, as CEOs question whether they are transforming fast enough
• The US remains the top destination for global investment, with interest in India doubling year-on-year

DAVOS, Switzerland, Jan. 20, 2026 /PRNewswire/ — CEO confidence in their company’s revenue prospects has fallen to its lowest level in five years, as business leaders grapple with uneven returns from artificial intelligence, rising geopolitical risk, and intensifying cyber threats.

According to PwC’s 29th Global CEO Survey, only three-in-ten (30%) CEOs say they are confident about revenue growth over the next 12 months—down from 38% in 2025 and 56% in 2022. The findings suggest that as CEOs navigate a complex operating environment shaped by rapid technological change, geopolitical uncertainty, and economic pressure, many companies have yet to translate investment into consistent financial gains.

The survey is based on responses from 4,454 CEOs across 95 countries and territories.

AI emerges as a defining fault line for growth and profitability

The biggest question on CEOs’ minds is whether they are transforming fast enough to keep pace with technological change, including AI. Forty-two percent cite this as their top concern—well ahead of worries about innovation capability or medium to long-term viability (both 29%).

Despite widespread experimentation, only one-in-eight (12%) CEOs say AI has delivered both cost and revenue benefits. Overall, 33% report gains in either cost or revenue, while 56% say they have seen no significant financial benefit to date.

The survey points to a growing divide between companies piloting AI and those deploying it at scale. CEOs reporting both cost and revenue gains are two to three times more likely to say they have embedded AI extensively across products and services, demand generation, and strategic decision-making.

Foundations matter as much as scale. CEOs whose organisations have established strong AI foundations—such as Responsible AI frameworks and technology environments that enable enterprise-wide integration—are three times more likely to report meaningful financial returns. Separate PwC analysis shows that companies applying AI widely to products, services, and customer experiences achieved nearly four percentage points higher profit margins than those that did not.

Mohamed Kande, PwC Global Chairman, said:

“2026 is shaping up as a decisive year for AI. A small group of companies are already turning AI into measurable financial returns, while many others are still struggling to move beyond pilots. That gap is starting to show up in confidence and competitiveness—and it will widen quickly for those that don’t act.”

Confidence falls as tariffs and cyber risks intensify

CEO confidence has softened further amid rising exposure to external risks. One-in-five CEOs globally (20%) say their organisation is highly or extremely exposed to the risk of significant financial loss from tariffs over the next 12 months, though exposure varies widely by region—from 6% across the Middle East to 28% in the Chinese Mainland and 35% in Mexico. Among US CEOs, 22% report high exposure.

Concern about cyber risk has risen sharply, with 31% of CEOs now citing it as a major threat—up from 24% last year and 21% two years ago. In response, 84% say they plan to strengthen enterprise-wide cybersecurity as part of their response to geopolitical risk.

Concerns about macroeconomic volatility (31%), technology disruption (24%), and geopolitics (23%) have also edged higher, while concern about inflation is marginally down (from 27% last year to 25%).

Reinvention becomes a strategic imperative

Despite the challenging outlook, CEOs increasingly see reinvention as essential to growth. More than four in ten (42%) say their company has begun competing in new sectors over the past five years. Among those planning major acquisitions, 44% expect to invest outside their current industry, with technology the most attractive adjacent sector.

A little over half of CEOs (51%) plan to make international investments in the year ahead. The United States remains the top destination, with 35% ranking it among their top three markets. The United Kingdom and Germany (both 13%) and the Chinese Mainland (11%) also feature prominently. Interest in India has nearly doubled year-on-year, with 13% of CEOs planning international investment placing it among their top three destinations.

Execution gaps remain. Only one in four CEOs say their organisation tolerates high risk in innovation projects, has disciplined processes to stop underperforming initiatives, or operates a defined innovation centre or corporate venturing function.

Time is also a constraint: CEOs report spending 47% of their time focused on issues with a horizon of less than one year, compared with just 16% on decisions looking more than five years ahead.

Mohamed Kande, PwC Global Chairman, added: 

“In periods of rapid change, the instinct to slow down is understandable—but it’s also risky. The value at stake across the global economy is increasing, and the window to capture it is narrowing. The companies that succeed will be those willing to make bold decisions and invest with conviction in the capabilities that matter most.”

Notes to Editors

About PwC’s 2026 Global CEO Survey

We surveyed 4,454 CEOs in 95 countries and territories from 30 September to 10 November 2025. The global and regional figures in this report are weighted proportionally to country nominal GDP, so CEOs’ views are broadly representative across all major regions. The industry- and country-level figures are based on unweighted data from the full sample of 4,454 CEOs. To learn more about the findings, please visit: http://www.pwc.com/ceosurvey.

About PwC 

At PwC, we help clients build trust and reinvent so they can turn complexity into competitive advantage. We’re a tech-forward, people-empowered network with more than 364,000 people in 136 countries and 137 territories. Across audit and assurance, tax and legal, deals and consulting, we help clients build, accelerate, and sustain momentum. Find out more at www.pwc.com.